Announcement PDF RNS Number : 9013U Genedrive PLC 27 November 2019 genedrive plc ("genedrive" or the "Company") Result of AGM genedrive plc (LSE: GDR), the near patient molecular diagnostics company, announces that at the Annual General Meeting, held today, all resolutions proposed were duly passed. For information, details of the proxy voting are shown below: Resolution Votes For Votes For (as % of votes cast) Votes Against 1. 22,673,789 100.0% 21,886,545 Receive the Annual report and accounts for the Company 2. Approve the Directors' Remuneration Report 3. Re-appoint Tom Lindsay as a director 4. Re-appoint Chris Yates as a director 5. Re-appoint David Budd as a director 6. Re-appoint Matthew Fowler as a director 7. Re-appoint Ian Gilham as a director 8. Appoint RSM UK as auditors of the Company 9. Directors' authority to allot shares 10. Disapplication of pre-emption rights Votes Withheld 0 Votes Against (as % of votes cast) 0.00% 96.5% 787,131 3.47% 628 22,674,304 100.0% 0 0.00% 0 22,674,304 100.0% 0 0.00% 0 22,674,304 100.0% 0 0.00% 0 22,674,304 100.0% 0 0.00% 0 21,887,370 100.0% 314 0.00% 786,620 22,674,304 100.0% 0 0.00% 0 22,109,087 100.0% 0 0.00% 565,217 19,551,681 88.4% 2,556,891 11.57% 565,732 515 The full text of each of the resolutions is set out in the notice of Annual General Meeting, copies of which are available on the Company's website (www.genedriveplc.com). - Ends For further details please contact: genedrive plc David Budd: CEO / Matthew Fowler: CFO www.genedriveplc.com +44 (0)161 989 0245 Peel Hunt LLP James Steel / Oliver Jackson +44 (0)20 7418 8900 Stanford Capital Partners Limited Patrick Claridge / John Howes +44 (0)20 3815 8880 Walbrook PR Ltd (Media Relations & Investor Relations) Paul McManus / Anna Dunphy +44 (0)20 7933 8780 or genedrive@walbrookpr.com +44 (0)7980 541 893 / +44 (0)7876 741 001 Notes to Editors About genedrive plc genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Genedrive® mt-RNR1-ID kit has received CE-IVD Certification and will be launched into Europe and other markets following full evaluation by the UK National Health Service. The Company has assays on market for the detection of HCV, certain military biological targets, and has tests in development for tuberculosis (mTB). This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. END RAGBLBDBGDDBGCR